Estimands for Continuous Longitudinal Outcomes in the Presence of Treatment Discontinuation—A Simulation Study in Hyperkalemia Treatments

References

• Abdalla, S., Montez-Rath, M. E., Parfrey, P. S., and Chertow, G. M. (2016), “The Win Ratio Approach to Analyzing Composite Outcomes: An Application to the EVOLVE Trial,” Contemporary Clinical Trials, 48, 119–124. DOI: 10.1016/j.cct.2016.04.001.
   PubMed Web of Science ®Google Scholar
• Bakris, G. L., Pitt, B., Weir, M. R., Freeman, M. W., Mayo, M. R., Garza, D., Stasiv, Y., Zawadzki, R., Berman, L., and Bushinsky, D. A. (2015), “Effect of Patiromer on Serum Potassium Level in Patients With Hyperkalemia and Diabetic Kidney. Disease: The AMETHYST-DN Randomized Clinical Trial,” JAMA, 314, 151–161. DOI: 10.1001/jama.2015.7446.
   PubMed Web of Science ®Google Scholar
• Berry, J. D., Miller, R., Moore, D. H., Cudkowicz, M. E., van den Berg, L. H., Kerr, D. A., Dong, Y., Ingersoll, E. W., and Archibald, D. (2013), “The Combined Assessment of Function and Survival (CAFS): A New Endpoint for ALS Clinical Trials,” Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 14, 162–168. DOI: 10.3109/21678421.2012.762930.
   PubMed Web of Science ®Google Scholar
• Brunner, E., Vandemeulebroecke, M., and Mütze, T. (2021), “Win Odds: An Adaptation of the Win Ratio to Include Ties,” Statistics in Medicine, 40, 3367–3384. DOI: 10.1002/sim.8967.
   PubMed Web of Science ®Google Scholar
• Buyse, M. (2010), “Generalized Pairwise Comparisons of Prioritized Outcomes in the Two-Sample Problem,” Statistics in Medicine, 29, 3245–3257. DOI: 10.1002/sim.3923.
   PubMed Web of Science ®Google Scholar
• CHMP (2017), “Assessment Report Veltassa,” available at https://www.ema.europa.eu/en/documents/assessment-report/veltassa-epar-public-assessment-report_en.pdf.
   Google Scholar
• Crans, G. G., and Shuster, J. J. (2008), “How Conservative is Fisher’s exact test? A Quantitative Evaluation of the Two-sample Comparative Binomial Trial,” Statistics in Medicine, 27, 3598–3611. DOI: 10.1002/sim.3221.
   PubMed Web of Science ®Google Scholar
• Elashoff, R. M., Li, G., and Li, N. (2007), “An Approach to Joint Analysis of Longitudinal Measurements and Competing Risks Failure Time Data,” Statistics in Medicine, 26, 2813–2835. DOI: 10.1002/sim.2749.
   PubMed Web of Science ®Google Scholar
• Evans, S. R., Rubin, D., Follmann, D., Pennello, G., Huskins, W. C., Powers, J. H., Schoenfeld, D., Chuang-Stein, C., Cosgrove, S. E., Fowler, V. G., Jr., Lautenbach, E., and Chambers, H. F. (2015), “Desirability of Outcome Ranking (DOOR) and Response Adjusted for Duration of Antibiotic Risk (RADAR),” Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America, 61, 800–806. DOI: 10.1093/cid/civ495.
   PubMed Web of Science ®Google Scholar
• Fan, C., Zhang, D., Wei, L., and Koch, G. (2016), “Methods for Missing Data Handling in Randomized Clinical Trials with Nonnormal Endpoints with Application to a Phase III Clinical Trial,” Statistics in Biopharmaceutical Research, 8, 179–193. DOI: 10.1080/19466315.2016.1142890.
   Web of Science ®Google Scholar
• Fergusson, N. A., Ramsay, T., Chasse, M., English, S. W., and Knoll, G. A. (2018), “The Win Ratio Approach Did Not Alter Study Conclusions and May Mitigate Concerns Regarding Unequal Composite End Points in Kidney Transplant Trials,” Journal of Clinical Epidemiology, 98, 9–15. DOI: 10.1016/j.jclinepi.2018.02.001.
   PubMed Web of Science ®Google Scholar
• Ferreira, J. P., Jhund, P. S., Duarte, K., Claggett, B. L., Solomon, S. D., Pocock, S., Petrie, M. C., Zannad, F., and McMurray, J. J. V. (2020), “Use of the Win Ratio in Cardiovascular Trials,” JACC Heart Failure, 8, 441–450. DOI: 10.1016/j.jchf.2020.02.010.
   PubMed Web of Science ®Google Scholar
• Finkelstein, D. M., and Schoenfeld, D. A. (1999), “Combining Mortality and Longitudinal Measures in Clinical Trials,” Statistics in Medicine, 18, 1341–1354. DOI: 10.1002/(SICI)1097-0258(19990615)18:11<1341::AID-SIM129>3.0.CO;2-7.
   PubMed Web of Science ®Google Scholar
• Fletcher, C., Tsuchiya, S., and Mehrotra, D. V. (2017), “Current Practices in Choosing Estimands and Sensitivity Analyses in Clinical Trials: Results of the ICH E9 Survey,” Therapeutic Innovation and Regulatory Science, 51, 69–76. DOI: 10.1177/2168479016666586.
   PubMed Web of Science ®Google Scholar
• Henderson, R., Diggle, P., and Dobson, A. (2000), “Joint Modelling of Longitudinal Measurements and Event Time Data,” Biostatistics (Oxford, England), 1, 465–480. DOI: 10.1093/biostatistics/1.4.465.
   PubMedGoogle Scholar
• ICH E9. (1998), “International Conference on Harmonisation Harmonised Tripartite Guideline E9: Statistical Principles for Clinical Trials,” available at http://www.ich.org.
   Google Scholar
• International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use. (2019), “E9 (R1): Addendum on Estimands and Sensitivity Analysis in Clinical Trials to the Guideline on Statistical Principles for Clinical Trials,” available at https://database.ich.org/sites/default/files/E9-R1_Step4_Guideline_2019_1203.pdf.
   Google Scholar
• Leuchs, A.-K., Zinserling, J., Brandt, A., Wirtz, D., and Benda, N. (2015), “Choosing Appropriate Estimands in Clinical Trials,” Therapeutic Innovation and Regulatory Science, 49, 584–592. DOI: 10.1177/2168479014567317.
   PubMed Web of Science ®Google Scholar
• Lim, E., Brown, A., Helmy, A., Mussa, S., and Altman, D. G. (2008), “Composite Outcomes in Cardiovascular Research: A Survey of Randomized Trials,” Annals of Internal Medicine, 149, 612–617. DOI: 10.7326/0003-4819-149-9-200811040-00004.
   PubMed Web of Science ®Google Scholar
• Mallinckrodt, C. H., Clark, W. S., and David, S. R. (2001), “Accounting for Dropout Bias Using Mixed-Effects Models,” Journal of Biopharmaceutical Statistics, 11, 9–21. DOI: 10.1081/BIP-100104194.
   PubMedGoogle Scholar
• Maurer, M. S., Schwartz, J. H., Gundapaneni, B., Elliott, P. M., Merlini, G., Waddington-Cruz, M., Kristen, A. V., Grogan, M., Witteles, R., Damy, T., Drachman, B. M., Shah, S. J., Hanna, M., Judge, D. P., Barsdorf, A. I., Huber, P., Patterson, T. A., Riley, S., Schumacher, J., Stewart, M., Sultan, M. B., and Rapezzi, C, ATTR-ACT Study Investigators. (2018), “Tafamidis Treatment for Patients with Transthyretin Amyloid Cardiomyopathy,” New England Journal of Medicine, 379, 1007–1016. DOI: 10.1056/NEJMoa1805689.
   PubMed Web of Science ®Google Scholar
• Molenberghs, G., Thijs, H., Jansen, I., Beunckens, C., Kenward, M. G., Mallinckrodt, C., and Carroll, R. J. (2004), “Analyzing Incomplete Longitudinal Clinical Trial Data,” Biostatistics (Oxford, England), 5, 445–464. DOI: 10.1093/biostatistics/kxh001.
   PubMed Web of Science ®Google Scholar
• Molnar, F. J., Man-Son-Hing, M., Hutton, B., and Fergusson, D. A. (2009), “Have Last Observation-Carried-Forward Analyses Caused us to Favor More Toxic Dementia Therapies Over Less Toxic Alternatives? A Systematic Review,” Open Medicine, 3, e31–e50.
   PubMedGoogle Scholar
• O’Brien, P. C., Zhang, D., and Bailey, K. R. (2005), “Semi-parametric and Nonparametric Methods for Clinical Trials with Incomplete Data,” Statistics in Medicine, 24, 341–358. DOI: 10.1002/sim.1963.
   PubMed Web of Science ®Google Scholar
• Pocock, S. J., Ariti, C. A., Collier, T. J., and Wang, D. (2012), “The Win Ratio: A New Approach to the Analysis of Composite Endpoints in Clinical Trials Based on Clinical Priorities,” European Heart Journal, 33, 176–182. DOI: 10.1093/eurheartj/ehr352.
   PubMed Web of Science ®Google Scholar
• Rogers, J. K., Pocock, S. J., McMurray, J. J. V., Granger, C. B., Michelson, E. L., Ostergren, J., Pfeffer, M. A., Solomon, S. D., Swedberg, K., and Yusuf, S. (2014), “Analysing Recurrent Hospitalizations in Heart Failure: A Review of Statistical Methodology, with Application to CHARM-Preserved,” European Journal of Heart Failure, 16, 33–40. DOI: 10.1002/ejhf.29.
   PubMed Web of Science ®Google Scholar
• Siddiqui, O., Hung, H. M., and O’Neill, R. (2009), “MMRM vs. LOCF: A Comprehensive Comparison Based on Simulation Study and 25 NDA Datasets,” Journal of Biopharmaceutical Statistics, 19, 227–246. DOI: 10.1080/10543400802609797.
   PubMed Web of Science ®Google Scholar
• Snapinn, S. M., and Jiang, Q. (2007), “Responder Analyses and the Assessment of A Clinically Relevant Treatment Effect,” Trials, 8, 31. DOI: 10.1186/1745-6215-8-31.
   PubMed Web of Science ®Google Scholar
• Tseng, C. H., and Wong, W. K. (2011), “Analysis of a Composite Endpoint with Longitudinal and Time-to-event Data,” Statistics in Medicine, 30, 1018–1027. DOI: 10.1002/sim.4199.
   PubMed Web of Science ®Google Scholar
• Ukyo, Y., Noma, H., Maruo, K., and Gosho, M. (2019), “Improved Small Sample Inference Methods for a Mixed-Effects Model for Repeated Measures Approach in Incomplete Longitudinal Data Analysis,” Stats, 2, 174–188. DOI: 10.3390/stats2020013.
   Google Scholar
• US Food and Drug Administration (2014), “Statistical Review(s) Veltassa,” available at https://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/205739Orig1s000StatR.pdf.
   Google Scholar
• US Food and Drug Administration (2016), “Statistical Review(s) Lokelma,” available at https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/207078Orig1s000StatR.pdf.
   Google Scholar
• Weir, M. R., Bakris, G. L., Bushinsky, D. A., Mayo, M. R., Garza, D., Stasiv, Y., Wittes, J., Christ-Schmidt, H., Berman, L., and Pitt, B. (2015), “Patiromer in Patients With Kidney Disease and Hyperkalemia Receiving RAAS Inhibitors,” New England Journal of Medicine, 372, 211–221. DOI: 10.1056/NEJMoa1410853.
   PubMed Web of Science ®Google Scholar
• Wittkop, L., Smith, C., Fox, Z., Sabin, C., Richert, L., Aboulker, J. P., Phillips, A., Chene, G., Babiker, A., and Thiebaut, R. (2010), “Methodological Issues in the Use of Composite Endpoints in Clinical Trials: Examples from the HIV Field,” Clinical Trials (London, England), 7, 19–35. DOI: 10.1177/1740774509356117.
   PubMed Web of Science ®Google Scholar
• Wong, W. K., Furst, D. E., Clements, P. J., and Streisand, J. B. (2007), “Assessing Disease Progression Using a Composite Endpoint,” Statistical Methods in Medical Research, 16, 31–49. DOI: 10.1177/0962280207070632.
   PubMed Web of Science ®Google Scholar